Vnitr Lek 2007, 53(9):925-927

Možnosti imunomodulační terapie u kriticky nemocných - lepší diagnostika znamená účinnější léčbu - editorial

M. Průcha
Oddělení klinické biochemie, hematologie a imunologie Nemocnice Na Homolce, Praha, přednosta prim. MUDr. Miroslav Průcha, Ph.D.

Received: February 15, 2007; Published: September 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Průcha M. Možnosti imunomodulační terapie u kriticky nemocných - lepší diagnostika znamená účinnější léčbu - editorial. Vnitr Lek. 2007;53(9):925-927.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Marshall JC Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nature Rev Drug Discovery 2003, 2: 391-405. Go to PubMed...
    2. Eichacker PQ, Parent C, Kalil A et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166: 1197-1205. Go to original source... Go to PubMed...
    3. Macias WL, Nelson DR, Wiliams M et al. Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. Critical Care 2005; 9: R607-R622. Go to original source... Go to PubMed...
    4. Dellinger RP, Carlet JM, Masur H et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004; 32: 858-873. Go to original source... Go to PubMed...
    5. Jenner RG, Young RA Insigths into host responses against pathogens from transcriptional profiling. Nature Rev Microbiology 2003; 3: 281-294. Go to original source... Go to PubMed...
    6. Nasraway SA The problems and challenges of immunotherapy in sepsis. Chest 2003; 123: 451S-459S. Go to original source... Go to PubMed...
    7. Opal SM Concept of PIRO as a new conceptual framework to understand sepsis. Pediatr Crit Care Med 2005; 6: S55-S60. Go to PubMed...
    8. Sterns T, Pollak N, Echtenacher B et al. Divergence of protection induced by bacterial products and sepsis-induced immune suppression. Infect Immun 2005; 73: 4905-4912. Go to original source... Go to PubMed...
    9. Sedlačková L, Průcha M, Dostál M Immunological monitoring of sepsis using flow cytometry - quantitation of monocyte HLA-DR expression and granulocyte CD64 expression. Epidemiol Mikrobiol Imunol 2005; 54: 54-61.
    10. Průcha M, Maťoška V PIRO koncept - "P" (predispozice) a sepse. Anesteziologie a intenzivní medicína 2005; 4: 203-210.
    11. Ojeda MO, van't Veer C, Ortega FCB et al. Dialyzable leukocyte extrakt differentially regulates the production of TNF-α, IL-6, and IL8 in bacterial component-activated leukocytes and endothelial cells. Inflamm Res 2005; 54: 74-81. Go to original source... Go to PubMed...
    12. Franco-Molina MA, Mendoza-Gamboa E, Castillo-Leon L et al. Bovine dialyzable leukocyte extract protects against LPS-induced, murine endotoxic shock. Int Immunopharmacol 2004; 4: 1577-1586. Go to original source... Go to PubMed...
    13. Prucha M, Ruryk A, Borris H et al. Expression profiling: toward an application in sepsis diagnostics. Shock 2004; 22: 29-33. Go to original source... Go to PubMed...
    14. Heuer JG, Cummins DJ, Edmonds BT Multiplex proteomic approaches to sepsis research: case studies employing new technologies. Expert Rev Proteomics 2005; 2: 669-680. Go to original source... Go to PubMed...
    15. Opal SM Active immunization with a detoxified endotoxine vaccine protects against lethal polymicrobial sepsis. Its use with CpG adjutant and potential mechanisms. J Infect Dis 2005; 192: 2074-2080.
    16. De Rosa G, Maiuri MC, Ungaro F et al: Enhanced intracellular uptake and inhibition of NF-κB activation by decoy oligonucleotide released from PLGA microspheres. J Gene Med 2005; 7: 771-781. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.